Immunome (IMNM) Stock: Insider Trades, Congress & Funds

Smart money at a glance

Filings to Oct 31, 2026

Net selling: insiders sold $5.7M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersSEC Form 4, last 90 days: -$5.7M netNet selling
CongressSTOCK Act, last 180 days: NoneNo trades disclosed
Big fundsSEC 13F, quarter ended Jun 30, 2026: 0 added, 1 cutMore cutting

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Questions about IMNM filings

Are insiders buying or selling Immunome Inc (IMNM) stock?

Net selling: insiders sold $5.7M and bought $0 of IMNM stock on the open market in the 90 days to Oct 31, 2026, according to SEC Form 4 filings. $5.7M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Barchas, Isaac (Director), who sold $3.1M. The latest filing was on Sep 15, 2026.

Which members of Congress have traded IMNM recently?

None. No member of Congress disclosed a IMNM trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this IMNM smart-money data?

This summary uses filings available on Oct 31, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

13F: filed up to 45 days late.

Smart money on IMNM

Lean short2 sources:
- Insiders
- Funds

Top traders
No tracked positions at the last update
Insiders
Lean short3 sales · $3.5M
3 of 3 on scheduled plans. Form 4 filings.
Politicians
No recent politician filings found
Funds
Lean short1 added · 2 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about IMNM filings

Are insiders buying or selling Immunome Inc (IMNM) stock?

Which members of Congress have traded IMNM recently?

None. No member of Congress disclosed a IMNM trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this IMNM smart-money data?

Funds

What funds are doing

6 moves · 6 mo

Buys/Adds$29.3MSells/Trims$233.7M

Buys/Adds (1)

BO
Bank of America
Q1 2026 13F
$12.7M
added
Signals like this: n=13770, 53% finished lower at D15, median -0.4% vs SPY -0.4%

Sells/Trims (2)

MW
Marshall Wace
Q2 2026 13F
$21.8M
trimmed
Signals like this: n=7469, 53% finished lower at D15, median -0.5% vs SPY -0.4%
P7
Point72
Steven Cohen · Q1 2026 13F
$151.1M
sold
Signals like this: n=2234, 53% finished lower at D15, median -0.5% vs SPY -0.4%

3 more moves

Pro opens all of them for $16.50/month, paid yearly.

Unlock all 3 moves

Unlock everything for $29/month

Unlock for $29/month

Reported Aug 11, 2026

Earnings came in 28.8% below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Aug 11, 2026

Period ending

Jun 30, 2026

Earnings per share

-$0.65-28.78% miss

-$0.50 expected

Revenue

$0.00

SEC filing

EPS: Yahoo Finance

Next report

Estimated report: Nov 5, 2026, in 5 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Jun 30, 2026Reported Aug 11, 2026	-$0.65est. -$0.50	-28.78%miss	$0.00SEC filing	-100.0%from $4.0M
Mar 31, 2026Reported May 12, 2026	-$0.48est. -$0.59	+19.48%beat	$0.00SEC filing	-100.0%from $2.9M
Dec 31, 2025Reported Mar 3, 2026	-$0.76est. -$0.57	-32.80%miss	$0.00Yahoo Finance	No year-ago quarter
Sep 30, 2025Reported Nov 6, 2025	-$0.65est. -$0.54	-19.63%miss	$0.00SEC filing	-100.0%from $2.9M
Jun 30, 2025Reported Aug 6, 2025	-$0.50est. -$0.50	+0.00%in line	$4.0MSEC filing	+69.8%from $2.4M
Mar 31, 2025Reported May 12, 2025	-$0.52est. -$0.57	+8.77%beat	$2.9MSEC filing	+184.4%from $1.0M
Dec 31, 2024Reported Mar 19, 2025	-$1.11est. -$0.61	-82.72%miss	$9.0M · FYSEC filing	No year-ago quarter
Sep 30, 2024Reported Nov 13, 2024	-$0.78est. -$0.58	-34.48%miss	$2.9MSEC filing	-18.4%from $3.6M

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $18.25
52-wk high: $30.06
High: $18.98
52-wk low: $14.64
Low: $17.82
Prev close: $18.29
Mkt cap: $2.16B
ROE: -64.0%
Beta: 2.56
P/S: 791.8x
P/B: 4.2x
Profit margin: +0.0%
Op margin: +0.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $2.2B

Valuation

P/S791.79
P/B4.22

Quality

Operating margin0.0%
ROE-64.0%
ROA-37.8%

Growth

Beta2.56

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

0 / 100

RSI 14

43balanced

20D volatility

61%annualized

52-week range

$18.21

$14.64$30.06

20D support

$16.41recent floor

20D resistance

$21.48recent ceiling

Returns

5D +1.2%20D -12.9%60D -29.5%

Price vs moving averages

SMA20 -0.8%SMA50 -18.9%SMA200 -19.0%

Volume pace

1.04xvs prior 20D

Smart money at a glance

Filings to Oct 31, 2026

Net selling: insiders sold $5.7M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersSEC Form 4, last 90 days: -$5.7M netNet selling
CongressSTOCK Act, last 180 days: NoneNo trades disclosed
Big fundsSEC 13F, quarter ended Jun 30, 2026: 0 added, 1 cutMore cutting

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Questions about IMNM filings

Are insiders buying or selling Immunome Inc (IMNM) stock?

Which members of Congress have traded IMNM recently?

None. No member of Congress disclosed a IMNM trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this IMNM smart-money data?

13F: filed up to 45 days late.

Smart money on IMNM

Lean short2 sources:
- Insiders
- Funds

Top traders
No tracked positions at the last update
Insiders
Lean short3 sales · $3.5M
3 of 3 on scheduled plans. Form 4 filings.
Politicians
No recent politician filings found
Funds
Lean short1 added · 2 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about IMNM filings

Are insiders buying or selling Immunome Inc (IMNM) stock?

Which members of Congress have traded IMNM recently?

None. No member of Congress disclosed a IMNM trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this IMNM smart-money data?

Funds

What funds are doing

6 moves · 6 mo

Buys/Adds$29.3MSells/Trims$233.7M

Buys/Adds (1)

BO
Bank of America
Q1 2026 13F
$12.7M
added
Signals like this: n=13770, 53% finished lower at D15, median -0.4% vs SPY -0.4%

Sells/Trims (2)

MW
Marshall Wace
Q2 2026 13F
$21.8M
trimmed
Signals like this: n=7469, 53% finished lower at D15, median -0.5% vs SPY -0.4%
P7
Point72
Steven Cohen · Q1 2026 13F
$151.1M
sold
Signals like this: n=2234, 53% finished lower at D15, median -0.5% vs SPY -0.4%

3 more moves

Pro opens all of them for $16.50/month, paid yearly.

Unlock all 3 moves

Unlock everything for $29/month

Unlock for $29/month

Reported Aug 11, 2026

Earnings came in 28.8% below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Aug 11, 2026

Period ending

Jun 30, 2026

Earnings per share

-$0.65-28.78% miss

-$0.50 expected

Revenue

$0.00

SEC filing

EPS: Yahoo Finance

Next report

Estimated report: Nov 5, 2026, in 5 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Jun 30, 2026Reported Aug 11, 2026	-$0.65est. -$0.50	-28.78%miss	$0.00SEC filing	-100.0%from $4.0M
Mar 31, 2026Reported May 12, 2026	-$0.48est. -$0.59	+19.48%beat	$0.00SEC filing	-100.0%from $2.9M
Dec 31, 2025Reported Mar 3, 2026	-$0.76est. -$0.57	-32.80%miss	$0.00Yahoo Finance	No year-ago quarter
Sep 30, 2025Reported Nov 6, 2025	-$0.65est. -$0.54	-19.63%miss	$0.00SEC filing	-100.0%from $2.9M
Jun 30, 2025Reported Aug 6, 2025	-$0.50est. -$0.50	+0.00%in line	$4.0MSEC filing	+69.8%from $2.4M
Mar 31, 2025Reported May 12, 2025	-$0.52est. -$0.57	+8.77%beat	$2.9MSEC filing	+184.4%from $1.0M
Dec 31, 2024Reported Mar 19, 2025	-$1.11est. -$0.61	-82.72%miss	$9.0M · FYSEC filing	No year-ago quarter
Sep 30, 2024Reported Nov 13, 2024	-$0.78est. -$0.58	-34.48%miss	$2.9MSEC filing	-18.4%from $3.6M

Open: $18.25
52-wk high: $30.06
High: $18.98
52-wk low: $14.64
Low: $17.82
Prev close: $18.29
Mkt cap: $2.16B
ROE: -64.0%
Beta: 2.56
P/S: 791.8x
P/B: 4.2x
Profit margin: +0.0%
Op margin: +0.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $2.2B

Valuation

P/S791.79
P/B4.22

Quality

Operating margin0.0%
ROE-64.0%
ROA-37.8%

Growth

Beta2.56

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

0 / 100

RSI 14

43balanced

20D volatility

61%annualized

52-week range

$18.21

$14.64$30.06

20D support

$16.41recent floor

20D resistance

$21.48recent ceiling

Returns

5D +1.2%20D -12.9%60D -29.5%

Price vs moving averages

SMA20 -0.8%SMA50 -18.9%SMA200 -19.0%

Volume pace

1.04xvs prior 20D

Immunome Inc

Smart money at a glance

What do analysts expect?

Questions about IMNM filings

Smart money on IMNM

Questions about IMNM filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 28.8% below what analysts expected.

Estimated report: Nov 5, 2026, in 5 days

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Immunome Inc

Smart money at a glance

What do analysts expect?

Questions about IMNM filings

Smart money on IMNM

Questions about IMNM filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 28.8% below what analysts expected.

Estimated report: Nov 5, 2026, in 5 days

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Immunome Inc

Overview

Questions about IMNM filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Immunome Inc

Overview

Questions about IMNM filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.